Our Products

Products

Our Products

Vaccine

Helps protect against

GARDASIL®

Human Papillomavirus diseases caused by 4 HPV Types

GARDASIL® 9

Human Papillomavirus diseases caused by 9 HPV Types

MMR-II®

Measles, Mumps, Rubella

PROQUOD®

Measles, Mumps, Rubella, Varicella

PNEUMOVAX 23®

Pneumococcal diseases

ROTATEQ®

Rotavirus Gastroenteritis

VAQTA®

Hepatitis A

VARIVAX®

Varicella (Chicken Pox)

ZOSTAVAX®

Shingles

 

Vaccines in Development

MSD currently has the following late-stage vaccine candidates in development:

An investigational, inactivated varicella zoster virus (VZV) vaccine candidate (V212) being evaluated for the prevention of herpes zoster and herpes zoster-related complications in select immunocompromised patient populations.

V920, the investigational Ebola vaccine candidate, was initially engineered with support from the Public Health Agency of Canada and then licensed to NewLink Genetics Corporation. MSD and NewLink Genetics’ Ebola vaccine candidate is currently being evaluated in Phase 1, 2 and 3 clinical studies in sites across the world, including three ongoing large-scale Phase 2/3 studies.

An investigational vaccine (V114) being evaluated for its ability to provide protection against pneumococcal disease caused by serotypes contained in the vaccine.